These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2412069)

  • 1. Comparison of blood pressure ratio by Doppler velocimetry and by plethysmography during treatment with ketanserin, a 5-HT2 receptor antagonist: a measure of improved collateral and microcirculatory flow.
    De Cree J; Leempoels J; Geukens H; Verhaegen H
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S92-4. PubMed ID: 2412069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication.
    De Cree J; Leempoels J; Geukens H; Verhaegen H
    Lancet; 1984 Oct; 2(8406):775-9. PubMed ID: 6148522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of post-thrombotic peripheral collateral circulation in the cat by ketanserin, a selective 5-HT2-receptor antagonist.
    Nevelsteen A; De Clerck F; Loots W; De Gryse A
    Arch Int Pharmacodyn Ther; 1984 Aug; 270(2):268-79. PubMed ID: 6486973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative haemodynamic effects of ketanserin and ritanserin in the proximal and distal upper limb circulations of hypertensive patients.
    Chau NP; Pithois-Merli I; Levenson J; Simon AC
    Eur J Clin Pharmacol; 1989; 37(3):215-20. PubMed ID: 2533074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ketanserin on macrocirculatory and microcirculatory blood flow in patients with intermittent claudication. A prospective randomized study.
    Beckers RC; Jörning PJ; Slaaf DW; Reneman RS; Jacobs MJ
    Eur J Clin Pharmacol; 1989; 37(3):295-6. PubMed ID: 2693113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo-controlled, double-blind, two-centre trial of ketanserin in intermittent claudication.
    Bounameaux H; Holditch T; Hellemans H; Berent A; Verhaeghe R
    Lancet; 1985 Dec; 2(8467):1268-71. PubMed ID: 2866336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ketanserin, a 5-HT2-receptor antagonist, on the blood flow response to temperature changes in the diabetic foot.
    Schneider SH; Tendler M; Apelian A; Jageneau AH; Khachadurian AK
    J Clin Pharmacol; 1985 Sep; 25(6):413-7. PubMed ID: 2932476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin-induced blood flow changes in the rat hindlegs after unilateral ligation of the femoral artery. Inhibition by the S2 receptor antagonist ketanserin.
    Verheyen A; Vlaminckx E; Lauwers F; Van Den Broeck C; Wouters L
    Arch Int Pharmacodyn Ther; 1984 Aug; 270(2):280-98. PubMed ID: 6486974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ketanserin on peripheral blood flow, haemorheology, and platelet function in patients with Raynaud's phenomenon.
    Longstaff J; Gush R; Williams EH; Jayson MI
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S99-101. PubMed ID: 2412071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study with the competitive 5-HT2-serotonergic antagonist ketanserin.
    Ferrara LA; Fasano ML; Rubba P; Soro S; Marotta G; Mancini M
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S159-60. PubMed ID: 2412041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute effect of ketanserin on the leg perfusion assessed by Doppler pressure measurements and 201Tl scintigraphy in patients with intermittent claudication.
    Bounameaux H; Devos P; Verhaeghe R
    J Cardiovasc Pharmacol; 1985; 7(6):1083-6. PubMed ID: 2418292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.
    Seibold JR; Jageneau AH
    Arthritis Rheum; 1984 Feb; 27(2):139-46. PubMed ID: 6365102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plethysmographic registration of volume changes in a hand vein. Effects of serotonin and of a specific antagonist.
    Jageneau AH; Hörig C; Loots W; Symoens J
    Angiology; 1980 Dec; 31(12):828-32. PubMed ID: 7469121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemorheological effects of ketanserin, a selective 5-HT2 receptor antagonist, in aged, spontaneously hypertensive dogs.
    De Clerck F; Jageneau A; Dom J
    Arch Int Pharmacodyn Ther; 1982 Jul; 258(1):100-15. PubMed ID: 7138138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketanserin and alpha 1-adrenergic antagonism in humans.
    Zabludowski JR; Ball SG; Robertson JI
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S123-5. PubMed ID: 2412032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular pharmacology of ketanserin.
    Van Nueten JM; Vanhoutte PM
    Bibl Cardiol; 1984; (38):222-33. PubMed ID: 6099724
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of the 5 HT2 antagonist ritanserin on blood pressure and serotonin-induced platelet aggregation in patients with untreated essential hypertension.
    Stott DJ; Saniabadi AR; Hosie J; Lowe GD; Ball SG
    Eur J Clin Pharmacol; 1988; 35(2):123-9. PubMed ID: 3142775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is ketanserin a D receptor antagonist?
    Lancet; 1983 Mar; 1(8326 Pt 1):703-4. PubMed ID: 6132056
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension.
    Zabludowski JR; Zoccali C; Isles CG; Murray GD; Robertson JI; Inglis GC; Fraser R; Ball SG
    Br J Clin Pharmacol; 1984 Mar; 17(3):309-16. PubMed ID: 6712863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular and blood gas responses to ketanserin in canine pulmonary edema induced by oleic acid.
    Koyama S; Kiyono S; Kayaba K; Kimura M; Nishizawa M
    Anesthesiology; 1985 Apr; 62(4):457-61. PubMed ID: 3157333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.